TruScreen’s real time technology has been found to be twice as sensitive as the Pap test and significantly more sensitive than HPV DNA testing at defining high grade cervical lesions in a real world setting.

Millions of women worldwide are unable to access cervical cancer screening.

Millions of women worldwide are unable to access cervical cancer screening.

Pap smear tests are ineffective in low-resource or developing health economies due to a lack of infrastructure, highly trained personnel required to read the smear and delays in reporting results, particularly in remote locations. Each year more than 270,000 women die from this disease.

Learn more

Cervical cancer is a major cause of morbidity and mortality worldwide.

Cervical cancer is a major cause of morbidity and mortality worldwide.

It is the second largest cause of deaths due to cancer in women. The death toll is greatest in populations that lack cervical cancer screening programmes. Worldwide, there are approximately 500,000 new cases of cervical cancer diagnosed and more than 270,000 die from this disease each year.

Learn more

TruScreen has been clinically tested by over 10,000 women around the world.

TruScreen has been clinically tested by over 10,000 women around the world.

Studies have involved women from Australia, Brazil, Italy, Philippines, People’s Republic of China, Russia, Singapore, South Africa, Spain, United Kingdom and the United States of America. More than 17 clinical trials involving 10,000 women have been completed worldwide.

Learn more

Better access to cervical cancer screening will save thousands of lives.

Better access to cervical cancer screening will save thousands of lives.

Cervical cancer develops from slowly progressing intraepithelial lesions. If early changes in cervical cells are detected through screening programmes, cervical cancer is curable. However, if undetected until late in its clinical course, it has a high death rate.

Learn more

TruScreen supports cervical screening in remote areas and developing countries.

TruScreen supports cervical screening in remote areas and developing countries.

For many women in remote areas and developing countries, poor access to cervical screening in clinics means many women go undetected until it is too late. TruScreen provides mobile units which are easy to use and do not require lab facilities in order to diagnose women.

Learn more

TruScreen performs equal to, or better than, alternative cervical screening tools.

TruScreen performs equal to, or better than, alternative cervical screening tools.

The performance of TruScreen has been tested in 17 clinical trials involving 10,000 women worldwide and was consistent and equal to, or better than in some studies, the comparing high quality cytology tests within the same study.

Learn more

In our most recent study, in Guadalajara, Mexico, TruScreen was found to be more than twice as sensitive as the Pap smear in identifying both low grade and high grade cervical lesions.

Back to top